The results of two phase III studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1 and VIEW 2]) suggest that intravitreal aflibercept (IVA) treatment is not inferior to intravitreal ranibizumab (IVR) treatment with regard to clinical outcomes9, 10. The gene discussed is VEGFA; the disease is age-related macular degeneration.